Julia C. Friend

900 total citations
18 papers, 598 citations indexed

About

Julia C. Friend is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Julia C. Friend has authored 18 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Julia C. Friend's work include Renal cell carcinoma treatment (10 papers), Renal and related cancers (6 papers) and Mitochondrial Function and Pathology (2 papers). Julia C. Friend is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Renal and related cancers (6 papers) and Mitochondrial Function and Pathology (2 papers). Julia C. Friend collaborates with scholars based in United States and Canada. Julia C. Friend's co-authors include Edward W. Cowen, Harry L. Malech, Suk See De Ravin, Nora Naumann, Karyl S. Barron, Ivan J. Fuss, Maria L. Turner, Martha Marquesen, Zhiqiong Yang and James E. Balow and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Julia C. Friend

18 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia C. Friend United States 9 297 233 161 129 88 18 598
Xi Zhan China 11 104 0.4× 468 2.0× 160 1.0× 38 0.3× 30 0.3× 28 841
Céline Villenet France 14 98 0.3× 176 0.8× 73 0.5× 25 0.2× 47 0.5× 31 472
Anne‐Kathrin Kienzler United Kingdom 13 658 2.2× 115 0.5× 134 0.8× 24 0.2× 182 2.1× 15 928
Maximilian Nitschké United States 10 374 1.3× 288 1.2× 64 0.4× 29 0.2× 15 0.2× 11 887
Yasuyoshi Miyao Japan 16 112 0.4× 319 1.4× 58 0.4× 42 0.3× 78 0.9× 49 639
Fujio Fujiki Japan 8 98 0.3× 202 0.9× 52 0.3× 38 0.3× 35 0.4× 11 556
K Braham France 7 146 0.5× 178 0.8× 120 0.7× 20 0.2× 99 1.1× 8 590
Fiona Connell United Kingdom 10 139 0.5× 296 1.3× 64 0.4× 25 0.2× 24 0.3× 15 916
Amy Beres United States 6 598 2.0× 126 0.5× 20 0.1× 64 0.5× 41 0.5× 9 870
Natalia Pikor Switzerland 15 521 1.8× 206 0.9× 43 0.3× 26 0.2× 46 0.5× 25 827

Countries citing papers authored by Julia C. Friend

Since Specialization
Citations

This map shows the geographic impact of Julia C. Friend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia C. Friend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia C. Friend more than expected).

Fields of papers citing papers by Julia C. Friend

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia C. Friend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia C. Friend. The network helps show where Julia C. Friend may publish in the future.

Co-authorship network of co-authors of Julia C. Friend

This figure shows the co-authorship network connecting the top 25 collaborators of Julia C. Friend. A scholar is included among the top collaborators of Julia C. Friend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia C. Friend. Julia C. Friend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Srinivasan, Ramaprasad, Sandeep Gurram, Eric A. Singer, et al.. (2025). Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. New England Journal of Medicine. 392(23). 2346–2356. 4 indexed citations
2.
Sharon, Elad, Julia C. Friend, Erin B. Purcell, et al.. (2022). A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).. Journal of Clinical Oncology. 40(16_suppl). TPS4604–TPS4604. 2 indexed citations
3.
Srinivasan, Ramaprasad, Sandeep Gurram, Eric A. Singer, et al.. (2020). Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. Journal of Clinical Oncology. 38(15_suppl). 5004–5004. 58 indexed citations
4.
Leger, Paul, Daniel M. Girardi, Julia C. Friend, et al.. (2020). A phase II study of the selective MET kinase inhibitor INC280 in advanced papillary renal cell cancer.. Journal of Clinical Oncology. 38(15_suppl). 5075–5075. 4 indexed citations
5.
Friend, Julia C., et al.. (2018). Handling Missing Values in Multivariate Time Series Classification. 1–3. 1 indexed citations
6.
Sidana, Abhinav, Amit Jain, Spencer Krane, et al.. (2017). Predictors of mortality in metastatic papillary renal cell cancer.. Journal of Clinical Oncology. 35(6_suppl). 509–509. 1 indexed citations
7.
Sidana, Abhinav, Julia C. Friend, L. Spencer Krane, et al.. (2016). Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urologic Oncology Seminars and Original Investigations. 35(3). 114.e9–114.e14. 5 indexed citations
8.
Friend, Julia C., et al.. (2015). Malignant ascites as a manifestation of advanced papillary renal cell cancer (pRCC).. Journal of Clinical Oncology. 33(7_suppl). 465–465. 1 indexed citations
9.
Fuss, Ivan J., Julia C. Friend, Zhiqiong Yang, et al.. (2013). Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency. Journal of Clinical Immunology. 33(4). 748–758. 86 indexed citations
10.
Stamatakis, Lambros, Brian Shuch, Eric A. Singer, et al.. (2013). Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). 4584–4584. 5 indexed citations
11.
Jacobs-El, Naima, Emily Y. Chew, Ramaprasad Srinivasan, et al.. (2012). Systemic Sunitinib Malate in the Treatment of Optic Nerve Hemangioblastomas. Investigative Ophthalmology & Visual Science. 53(14). 4940–4940. 1 indexed citations
12.
Shuch, Brian, Srinivas Vourganti, Julia C. Friend, et al.. (2012). Targeting the mTOR pathway in Chromophobe Kidney Cancer. Journal of Cancer. 3. 152–157. 18 indexed citations
13.
Singer, Eric A., Julia C. Friend, Cathy D. Vocke, et al.. (2012). A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer (RCC).. Journal of Clinical Oncology. 30(15_suppl). TPS4680–TPS4680. 19 indexed citations
14.
Ravin, Suk See De, Nora Naumann, Edward W. Cowen, et al.. (2008). Chronic granulomatous disease as a risk factor for autoimmune disease. Journal of Allergy and Clinical Immunology. 122(6). 1097–1103. 159 indexed citations
15.
Mannon, Peter, Ivan J. Fuss, Julia C. Friend, et al.. (2006). Excess IL-12 but not IL-23 Accompanies the Inflammatory Bowel Disease Associated With Common Variable Immunodeficiency. Gastroenterology. 131(3). 748–756. 70 indexed citations
16.
Ravin, Suk See De, Nora Naumann, M. Robinson, et al.. (2006). Sarcoidosis in Chronic Granulomatous Disease. PEDIATRICS. 117(3). e590–e595. 31 indexed citations
17.
Gómez‐Tortosa, Estrella, Marcy E. MacDonald, Julia C. Friend, et al.. (2001). Quantitative neuropathological changes in presymptomatic Huntington's disease. Annals of Neurology. 49(1). 29–34. 10 indexed citations
18.
MacDonald, Marcy E., Julia C. Friend, Sherryl A. Taylor, et al.. (2001). Quantitative neuropathological changes in presymptomatic Huntington's disease. Annals of Neurology. 49(1). 29–34. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xi Zhan Breakdown of academic impact, for papers by Céline Villenet Breakdown of academic impact, for papers by Anne‐Kathrin Kienzler Breakdown of academic impact, for papers by Maximilian Nitschké Breakdown of academic impact, for papers by Yasuyoshi Miyao Breakdown of academic impact, for papers by Fujio Fujiki Breakdown of academic impact, for papers by K Braham Breakdown of academic impact, for papers by Fiona Connell Breakdown of academic impact, for papers by Amy Beres Breakdown of academic impact, for papers by Natalia Pikor
Rankless by CCL
2026